Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

Chiara Bampo, Alessandra Alessi, Simona Fantini, Gaia Bertarelli, Filippo De Braud, Emilio Bombardieri, Francesca Valvo, Flavio Crippa, Maria Di Bartolomeo, Luigi Mariani, Massimo Milione, Pamela Biondani, Barbara Avuzzi, Chiara Chiruzzi, Filippo Pietrantonio

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: Our aim was to assess FDG-PET/CT as a surrogate biomarker of the pathological complete response in locally advanced rectal cancer treated with neoadjuvant chemoradiation. Methods: T3-4 and/or N+ rectal cancer patients were treated prospectively with capecitabine-based chemoradiation and total mesorectal excision 7-8 weeks later. FDG-PET/CT uptake was obtained at baseline, after 2 weeks, and 6 weeks following treatment completion, calculating the maximum standardized uptake value (SUV) and percentage difference to identify the early and late metabolic 'response index'. Results: Thirty-one patients were treated from January 2009 to January 2012 at the Istituto Nazionale dei Tumori of Milan. One patient was excluded due to surgery refusal. The pathological complete response rate was 30%. Early FDG-PET/CT was performed in 24 consenting patients and failed to show predictive utility. On the contrary, significant differences in late SUV value and response index were observed between complete and noncomplete pathological responders (p = 0.0006 and 0.03). In multivariate analysis including most relevant SUV parameters, none of them was independently associated with a pathological complete response. With receiver operating characteristic curve analysis, a late SUV threshold

Original languageEnglish
Pages (from-to)191-199
Number of pages9
JournalOncology
Volume84
Issue number4
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Rectal Neoplasms
ROC Curve
Multivariate Analysis
Biomarkers
Capecitabine
Therapeutics

Keywords

  • Capecitabine
  • Complete response
  • Pathology
  • PET
  • Predictive factor
  • Radiochemotherapy
  • Rectal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? / Bampo, Chiara; Alessi, Alessandra; Fantini, Simona; Bertarelli, Gaia; De Braud, Filippo; Bombardieri, Emilio; Valvo, Francesca; Crippa, Flavio; Di Bartolomeo, Maria; Mariani, Luigi; Milione, Massimo; Biondani, Pamela; Avuzzi, Barbara; Chiruzzi, Chiara; Pietrantonio, Filippo.

In: Oncology, Vol. 84, No. 4, 03.2013, p. 191-199.

Research output: Contribution to journalArticle

@article{fa226f9a9542458faad92c2972a012f2,
title = "Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?",
abstract = "Objectives: Our aim was to assess FDG-PET/CT as a surrogate biomarker of the pathological complete response in locally advanced rectal cancer treated with neoadjuvant chemoradiation. Methods: T3-4 and/or N+ rectal cancer patients were treated prospectively with capecitabine-based chemoradiation and total mesorectal excision 7-8 weeks later. FDG-PET/CT uptake was obtained at baseline, after 2 weeks, and 6 weeks following treatment completion, calculating the maximum standardized uptake value (SUV) and percentage difference to identify the early and late metabolic 'response index'. Results: Thirty-one patients were treated from January 2009 to January 2012 at the Istituto Nazionale dei Tumori of Milan. One patient was excluded due to surgery refusal. The pathological complete response rate was 30{\%}. Early FDG-PET/CT was performed in 24 consenting patients and failed to show predictive utility. On the contrary, significant differences in late SUV value and response index were observed between complete and noncomplete pathological responders (p = 0.0006 and 0.03). In multivariate analysis including most relevant SUV parameters, none of them was independently associated with a pathological complete response. With receiver operating characteristic curve analysis, a late SUV threshold",
keywords = "Capecitabine, Complete response, Pathology, PET, Predictive factor, Radiochemotherapy, Rectal cancer",
author = "Chiara Bampo and Alessandra Alessi and Simona Fantini and Gaia Bertarelli and {De Braud}, Filippo and Emilio Bombardieri and Francesca Valvo and Flavio Crippa and {Di Bartolomeo}, Maria and Luigi Mariani and Massimo Milione and Pamela Biondani and Barbara Avuzzi and Chiara Chiruzzi and Filippo Pietrantonio",
year = "2013",
month = "3",
doi = "10.1159/000345601",
language = "English",
volume = "84",
pages = "191--199",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

AU - Bampo, Chiara

AU - Alessi, Alessandra

AU - Fantini, Simona

AU - Bertarelli, Gaia

AU - De Braud, Filippo

AU - Bombardieri, Emilio

AU - Valvo, Francesca

AU - Crippa, Flavio

AU - Di Bartolomeo, Maria

AU - Mariani, Luigi

AU - Milione, Massimo

AU - Biondani, Pamela

AU - Avuzzi, Barbara

AU - Chiruzzi, Chiara

AU - Pietrantonio, Filippo

PY - 2013/3

Y1 - 2013/3

N2 - Objectives: Our aim was to assess FDG-PET/CT as a surrogate biomarker of the pathological complete response in locally advanced rectal cancer treated with neoadjuvant chemoradiation. Methods: T3-4 and/or N+ rectal cancer patients were treated prospectively with capecitabine-based chemoradiation and total mesorectal excision 7-8 weeks later. FDG-PET/CT uptake was obtained at baseline, after 2 weeks, and 6 weeks following treatment completion, calculating the maximum standardized uptake value (SUV) and percentage difference to identify the early and late metabolic 'response index'. Results: Thirty-one patients were treated from January 2009 to January 2012 at the Istituto Nazionale dei Tumori of Milan. One patient was excluded due to surgery refusal. The pathological complete response rate was 30%. Early FDG-PET/CT was performed in 24 consenting patients and failed to show predictive utility. On the contrary, significant differences in late SUV value and response index were observed between complete and noncomplete pathological responders (p = 0.0006 and 0.03). In multivariate analysis including most relevant SUV parameters, none of them was independently associated with a pathological complete response. With receiver operating characteristic curve analysis, a late SUV threshold

AB - Objectives: Our aim was to assess FDG-PET/CT as a surrogate biomarker of the pathological complete response in locally advanced rectal cancer treated with neoadjuvant chemoradiation. Methods: T3-4 and/or N+ rectal cancer patients were treated prospectively with capecitabine-based chemoradiation and total mesorectal excision 7-8 weeks later. FDG-PET/CT uptake was obtained at baseline, after 2 weeks, and 6 weeks following treatment completion, calculating the maximum standardized uptake value (SUV) and percentage difference to identify the early and late metabolic 'response index'. Results: Thirty-one patients were treated from January 2009 to January 2012 at the Istituto Nazionale dei Tumori of Milan. One patient was excluded due to surgery refusal. The pathological complete response rate was 30%. Early FDG-PET/CT was performed in 24 consenting patients and failed to show predictive utility. On the contrary, significant differences in late SUV value and response index were observed between complete and noncomplete pathological responders (p = 0.0006 and 0.03). In multivariate analysis including most relevant SUV parameters, none of them was independently associated with a pathological complete response. With receiver operating characteristic curve analysis, a late SUV threshold

KW - Capecitabine

KW - Complete response

KW - Pathology

KW - PET

KW - Predictive factor

KW - Radiochemotherapy

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84872261412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872261412&partnerID=8YFLogxK

U2 - 10.1159/000345601

DO - 10.1159/000345601

M3 - Article

C2 - 23328390

AN - SCOPUS:84872261412

VL - 84

SP - 191

EP - 199

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -